<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25100827</PMID><DateCompleted><Year>2014</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>88</Volume><Issue>20</Issue><PubDate><Year>2014</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Inhibition of enterovirus 71 by adenosine analog NITD008.</ArticleTitle><Pagination><StartPage>11915</StartPage><EndPage>11923</EndPage><MedlinePgn>11915-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01207-14</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) is a major viral pathogen in China and Southeast Asia. There is no clinically approved vaccine or antiviral therapy for EV71 infection. NITD008, an adenosine analog, is an inhibitor of flavivirus that blocks viral RNA synthesis. Here we report that NITD008 has potent antiviral activity against EV71. In cell culture, the compound inhibits EV71 at a 50% effective concentration of 0.67 &#x3bc;M and a 50% cytotoxic concentration of 119.97 &#x3bc;M. When administered at 5 mg/kg in an EV71 mouse model, the compound reduced viral loads in various organs and completely prevented clinical symptoms and death. To study the antiviral mechanism and drug resistance, we selected escape mutant viruses by culturing EV71 with increasing concentrations of NITD008. Resistance mutations were reproducibly mapped to the viral 3A and 3D polymerase regions. Resistance analysis with recombinant viruses demonstrated that either a 3A or a 3D mutation alone could lead to resistance to NITD008. A combination of both 3A and 3D mutations conferred higher resistance, suggesting a collaborative interplay between the 3A and 3D proteins during viral replication. The resistance results underline the importance of combination therapy required for EV71 treatment. Importance: Human enterovirus 71 (EV71) has emerged as a major cause of viral encephalitis in children worldwide, especially in the Asia-Pacific region. Vaccines and antivirals are urgently needed to prevent and treat EV71 infections. In this study, we report the in vitro and in vivo efficacy of NITD008 (an adenosine analog) as an inhibitor of EV71. The efficacy results validated the potential of nucleoside analogs as antiviral drugs for EV71 infections. Mechanistically, we showed that mutations in the viral 3A and 3D polymerases alone or in combination could confer resistance to NITD008. The resistance results suggest an intrinsic interaction between viral proteins 3A and 3D during replication, as well as the importance of combination therapy for the treatment of EV71 infections.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Cheng-Lin</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>CAS Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China Key Laboratory of Agricultural and Environmental Microbiology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeo</LastName><ForeName>Huimin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Yong Loo Lin School of Medicine, Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Han-Qing</ForeName><Initials>HQ</Initials><AffiliationInfo><Affiliation>CAS Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Si-Qing</ForeName><Initials>SQ</Initials><AffiliationInfo><Affiliation>CAS Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China Key Laboratory of Agricultural and Environmental Microbiology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shang</LastName><ForeName>Bao-Di</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>CAS Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>CAS Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alonso</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Yong Loo Lin School of Medicine, Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Pei-Yong</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>Novartis Institute for Tropical Diseases, Singapore zhangbo@wh.iov.cn pei_yong.shi@novartis.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>CAS Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China Key Laboratory of Agricultural and Environmental Microbiology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China zhangbo@wh.iov.cn pei_yong.shi@novartis.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>08</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000593137">NITD008</NameOfSubstance></Chemical><Chemical><RegistryNumber>K72T3FS567</RegistryNumber><NameOfSubstance UI="D000241">Adenosine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000241" MajorTopicYN="N">Adenosine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010948" MajorTopicYN="N">Viral Plaque Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25100827</ArticleId><ArticleId IdType="pmc">PMC4178731</ArticleId><ArticleId IdType="doi">10.1128/JVI.01207-14</ArticleId><ArticleId IdType="pii">JVI.01207-14</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mao Q, Wang Y, Yao X, Bian L, Wu X, Xu M, Liang Z. 2014. Coxsackievirus A16: epidemiology, diagnosis, and vaccine. Hum. Vaccin. Immunother. 10:360&#x2013;367. 10.4161/hv.27087</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.27087</ArticleId><ArticleId IdType="pmc">PMC4185891</ArticleId><ArticleId IdType="pubmed">24231751</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. 2009. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat. Med. 15:794&#x2013;797. 10.1038/nm.1961</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1961</ArticleId><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt NJ, Lennette EH, Ho HH. 1974. An apparently new enterovirus isolated from patients with disease of the central nervous system. J. Infect. Dis. 129:304&#x2013;309. 10.1093/infdis/129.3.304</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/129.3.304</ArticleId><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, Hu Y, Ji T, Song L, Liang Q, Zhang B, Gao Q, Li J, Wang S, Hu Y, Gu S, Zhang J, Yao G, Gu J, Wang X, Zhou Y, Chen C, Zhang M, Cao M, Wang J, Wang H, Wang N. 2014. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N. Engl. J. Med. 370:818&#x2013;828. 10.1056/NEJMoa1304923</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JX, Mao QY, Liang ZL, Ji H, Zhu FC. 2014. Development of enterovirus 71 vaccines: from the lab bench to phase III clinical trials. Expert Rev. Vaccines 13:609&#x2013;618. 10.1586/14760584.2014.897617</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2014.897617</ArticleId><ArticleId IdType="pubmed">24621093</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul AV, Rieder E, Kim DW, van Boom JH, Wimmer E. 2000. Identification of an RNA hairpin in poliovirus RNA that serves as the primary template in the in vitro uridylylation of VPg. J. Virol. 74:10359&#x2013;10370. 10.1128/JVI.74.22.10359-10370.2000</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.74.22.10359-10370.2000</ArticleId><ArticleId IdType="pmc">PMC110910</ArticleId><ArticleId IdType="pubmed">11044080</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma AM, Thibaut HJ, van der Linden L, Lanke K, Heggermont W, Ireland S, Andrews R, Arimilli M, Al-Tel TH, De Clercq E, van Kuppeveld F, Neyts J. 2009. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob. Agents Chemother. 53:1850&#x2013;1857. 10.1128/AAC.00934-08</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00934-08</ArticleId><ArticleId IdType="pmc">PMC2681499</ArticleId><ArticleId IdType="pubmed">19237651</ArticleId></ArticleIdList></Reference><Reference><Citation>Thibaut HJ, De Palma AM, Neyts J. 2012. Combating enterovirus replication: state-of-the-art on antiviral research. Biochem. Pharmacol. 83:185&#x2013;192. 10.1016/j.bcp.2011.08.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2011.08.016</ArticleId><ArticleId IdType="pubmed">21889497</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu KX, Ng MM, Chu JJ. 2010. Developments towards antiviral therapies against enterovirus 71. Drug Discov. Today 15:1041&#x2013;1051. 10.1016/j.drudis.2010.10.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2010.10.008</ArticleId><ArticleId IdType="pmc">PMC7108380</ArticleId><ArticleId IdType="pubmed">20974282</ArticleId></ArticleIdList></Reference><Reference><Citation>Kok CC, Phuektes P, Bek E, McMinn PC. 2012. Modification of the untranslated regions of human enterovirus 71 impairs growth in a cell-specific manner. J. Virol. 86:542&#x2013;552. 10.1128/JVI.00069-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00069-11</ArticleId><ArticleId IdType="pmc">PMC3255918</ArticleId><ArticleId IdType="pubmed">22031931</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo RL, Shih SR. 2013. Strategies to develop antivirals against enterovirus 71. Virol. J. 10:28. 10.1186/1743-422X-10-28</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-10-28</ArticleId><ArticleId IdType="pmc">PMC3614426</ArticleId><ArticleId IdType="pubmed">23339605</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden FG, Andries K, Janssen PA. 1992. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob. Agents Chemother. 36:727&#x2013;732. 10.1128/AAC.36.4.727</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.36.4.727</ArticleId><ArticleId IdType="pmc">PMC189373</ArticleId><ArticleId IdType="pubmed">1503435</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnard DL, Hubbard VD, Smee DF, Sidwell RW, Watson KG, Tucker SP, Reece PA. 2004. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrob. Agents Chemother. 48:1766&#x2013;1772. 10.1128/AAC.48.5.1766-1772.2004</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.48.5.1766-1772.2004</ArticleId><ArticleId IdType="pmc">PMC400527</ArticleId><ArticleId IdType="pubmed">15105133</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih SR, Tsai MC, Tseng SN, Won KF, Shia KS, Li WT, Chern JH, Chen GW, Lee CC, Lee YC, Peng KC, Chao YS. 2004. Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone. Antimicrob. Agents Chemother. 48:3523&#x2013;3529. 10.1128/AAC.48.9.3523-3529.2004</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.48.9.3523-3529.2004</ArticleId><ArticleId IdType="pmc">PMC514779</ArticleId><ArticleId IdType="pubmed">15328120</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, Zalman LS, Hendrickson TF, Love RA, Prins TJ, Marakovits JT, Zhou R, Tikhe J, Ford CE, Meador JW, Ferre RA, Brown EL, Binford SL, Brothers MA, DeLisle DM, Worland ST. 1999. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc. Natl. Acad. Sci. U. S. A. 96:11000&#x2013;11007. 10.1073/pnas.96.20.11000</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.20.11000</ArticleId><ArticleId IdType="pmc">PMC34232</ArticleId><ArticleId IdType="pubmed">10500114</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu G, Qi J, Chen Z, Xu X, Gao F, Lin D, Qian W, Liu H, Jiang H, Yan J, Gao GF. 2011. Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J. Virol. 85:10319&#x2013;10331. 10.1128/JVI.00787-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00787-11</ArticleId><ArticleId IdType="pmc">PMC3196414</ArticleId><ArticleId IdType="pubmed">21795339</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishimoto C, Crumpacker CS, Abelmann WH. 1988. Ribavirin treatment of murine coxsackievirus B3 myocarditis with analyses of lymphocyte subsets. J. Am. Coll. Cardiol. 12:1334&#x2013;1341. 10.1016/0735-1097(88)92618-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0735-1097(88)92618-6</ArticleId><ArticleId IdType="pubmed">2844874</ArticleId></ArticleIdList></Reference><Reference><Citation>Goris N, De Palma A, Toussaint JF, Musch I, Neyts J, De Clercq K. 2007. 2&#x2032;-C-methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus. Antiviral Res. 73:161&#x2013;168. 10.1016/j.antiviral.2006.09.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2006.09.007</ArticleId><ArticleId IdType="pubmed">17055073</ArticleId></ArticleIdList></Reference><Reference><Citation>Graci JD, Too K, Smidansky ED, Edathil JP, Barr EW, Harki DA, Galarraga JE, Bollinger JM, Jr, Peterson BR, Loakes D, Brown DM, Cameron CE. 2008. Lethal mutagenesis of picornaviruses with N-6-modified purine nucleoside analogues. Antimicrob. Agents Chemother. 52:971&#x2013;979. 10.1128/AAC.01056-07</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01056-07</ArticleId><ArticleId IdType="pmc">PMC2258490</ArticleId><ArticleId IdType="pubmed">18180344</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong WX, Yan B, Yeo H, Tan EL, Lee JJ, Ng JK, Chow VT, Alonso S. 2012. A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J. Virol. 86:2121&#x2013;2131. 10.1128/JVI.06103-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.06103-11</ArticleId><ArticleId IdType="pmc">PMC3302383</ArticleId><ArticleId IdType="pubmed">22130542</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Z, Chen YL, Schul W, Wang QY, Gu F, Duraiswamy J, Kondreddi RR, Niyomrattanakit P, Lakshminarayana SB, Goh A, Xu HY, Liu W, Liu B, Lim JY, Ng CY, Qing M, Lim CC, Yip A, Wang G, Chan WL, Tan HP, Lin K, Zhang B, Zou G, Bernard KA, Garrett C, Beltz K, Dong M, Weaver M, He H, Pichota A, Dartois V, Keller TH, Shi PY. 2009. An adenosine nucleoside inhibitor of dengue virus. Proc. Natl. Acad. Sci. U. S. A. 106:20435&#x2013;20439. 10.1073/pnas.0907010106</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0907010106</ArticleId><ArticleId IdType="pmc">PMC2787148</ArticleId><ArticleId IdType="pubmed">19918064</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang B, Deng C, Ye H, Xu W, Yuan Z, Shi PY, Zhang B. 2013. Development and characterization of a stable eGFP enterovirus 71 for antiviral screening. Antiviral Res. 97:198&#x2013;205. 10.1016/j.antiviral.2012.12.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2012.12.010</ArticleId><ArticleId IdType="pubmed">23267829</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Poh CL, Chow VT. 2002. Complete sequence analyses of enterovirus 71 strains from fatal and non-fatal cases of the hand, foot and mouth disease outbreak in Singapore (2000). Microbiol. Immunol. 46:801&#x2013;808. 10.1111/j.1348-0421.2002.tb02767.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1348-0421.2002.tb02767.x</ArticleId><ArticleId IdType="pubmed">12516778</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong WX, Yan B, Yeo HM, Tan EL, Lee JJ, Ng JK, Chow VT, Alonso S. 2012. A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J. Virol. 86:2121&#x2013;2131. 10.1128/JVI.06103-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.06103-11</ArticleId><ArticleId IdType="pmc">PMC3302383</ArticleId><ArticleId IdType="pubmed">22130542</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YJ, Chang YC, Hsiao NW, Hsieh JL, Wang CY, Kung SH, Tsai FJ, Lan YC, Lin CW. 2012. Fisetin and rutin as 3C protease inhibitors of enterovirus A71. J. Virol. Methods 182:93&#x2013;98. 10.1016/j.jviromet.2012.03.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2012.03.020</ArticleId><ArticleId IdType="pubmed">22465253</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Fan T, Yao X, Wu Z, Guo L, Lei X, Wang M, Jin Q, Cui S. 2011. Crystal structures of enterovirus 71 3C protease complexed with rupintrivir reveal the roles of catalytically important residues. J. Virol. 85:10021&#x2013;10030. 10.1128/JVI.05107-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.05107-11</ArticleId><ArticleId IdType="pmc">PMC3196404</ArticleId><ArticleId IdType="pubmed">21813612</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyssen P, Balzarini J, De Clercq E, Neyts J. 2005. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J. Virol. 79:1943&#x2013;1947. 10.1128/JVI.79.3.1943-1947.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.3.1943-1947.2005</ArticleId><ArticleId IdType="pmc">PMC544097</ArticleId><ArticleId IdType="pubmed">15650220</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty S, Cameron CE, Andino R. 2001. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. U. S. A. 98:6895&#x2013;6900. 10.1073/pnas.111085598</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.111085598</ArticleId><ArticleId IdType="pmc">PMC34449</ArticleId><ArticleId IdType="pubmed">11371613</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, Liang TJ. 2011. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 53:32&#x2013;41. 10.1002/hep.23985</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.23985</ArticleId><ArticleId IdType="pmc">PMC3498496</ArticleId><ArticleId IdType="pubmed">21254160</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AA, Peersen OB. 2004. Structural basis for proteolysis-dependent activation of the poliovirus RNA-dependent RNA polymerase. EMBO J. 23:3462&#x2013;3471. 10.1038/sj.emboj.7600357</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7600357</ArticleId><ArticleId IdType="pmc">PMC516629</ArticleId><ArticleId IdType="pubmed">15306852</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer JK, Kirkegaard K. 2003. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc. Natl. Acad. Sci. U. S. A. 100:7289&#x2013;7294. 10.1073/pnas.1232294100</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1232294100</ArticleId><ArticleId IdType="pmc">PMC165868</ArticleId><ArticleId IdType="pubmed">12754380</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghipour S, Bek EJ, McMinn PC. 2013. Ribavirin-resistant mutants of human enterovirus 71 express a high replication fidelity phenotype during growth in cell culture. J. Virol. 87:1759&#x2013;1769. 10.1128/JVI.02139-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02139-12</ArticleId><ArticleId IdType="pmc">PMC3554166</ArticleId><ArticleId IdType="pubmed">23175376</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong P, Kortus MG, Nix JC, Davis RE, Peersen OB. 2013. Structures of coxsackievirus, rhinovirus, and poliovirus polymerase elongation complexes solved by engineering RNA mediated crystal contacts. PLoS One 8(5):e60272. 10.1371/journal.pone.0060272</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0060272</ArticleId><ArticleId IdType="pmc">PMC3648537</ArticleId><ArticleId IdType="pubmed">23667424</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong P, Peersen OB. 2010. Structural basis for active site closure by the poliovirus RNA-dependent RNA polymerase. Proc. Natl. Acad. Sci. U. S. A. 107:22505&#x2013;22510. 10.1073/pnas.1007626107</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1007626107</ArticleId><ArticleId IdType="pmc">PMC3012486</ArticleId><ArticleId IdType="pubmed">21148772</ArticleId></ArticleIdList></Reference><Reference><Citation>Barton DJ, Morasco BJ, Eisner-Smerage L, Collis PS, Diamond SE, Hewlett MJ, Merchant MA, O'Donnell BJ, Flanegan JB. 1996. Poliovirus RNA polymerase mutation 3D-M394T results in a temperature-sensitive defect in RNA synthesis. Virology 217:459&#x2013;469. 10.1006/viro.1996.0140</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1996.0140</ArticleId><ArticleId IdType="pubmed">8610437</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison DN, Gazina EV, Purcell DF, Anderson DA, Petrou S. 2008. Amiloride derivatives inhibit coxsackievirus B3 RNA replication. J. Virol. 82:1465&#x2013;1473. 10.1128/JVI.01374-07</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01374-07</ArticleId><ArticleId IdType="pmc">PMC2224459</ArticleId><ArticleId IdType="pubmed">18032495</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazina EV, Smidansky ED, Holien JK, Harrison DN, Cromer BA, Arnold JJ, Parker MW, Cameron CE, Petrou S. 2011. Amiloride is a competitive inhibitor of coxsackievirus B3 RNA polymerase. J. Virol. 85:10364&#x2013;10374. 10.1128/JVI.05022-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.05022-11</ArticleId><ArticleId IdType="pmc">PMC3196452</ArticleId><ArticleId IdType="pubmed">21795353</ArticleId></ArticleIdList></Reference><Reference><Citation>Giachetti C, Hwang SS, Semler BL. 1992. cis-Acting lesions targeted to the hydrophobic domain of a poliovirus membrane protein involved in RNA replication. J. Virol. 66:6045&#x2013;6057</Citation><ArticleIdList><ArticleId IdType="pmc">PMC241482</ArticleId><ArticleId IdType="pubmed">1326655</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Franco D, Paul AV, Wimmer E. 2007. Tyrosine 3 of poliovirus terminal peptide VPg(3B) has an essential function in RNA replication in the context of its precursor protein, 3AB. J. Virol. 81:5669&#x2013;5684. 10.1128/JVI.02350-06</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02350-06</ArticleId><ArticleId IdType="pmc">PMC1900252</ArticleId><ArticleId IdType="pubmed">17360746</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul AV, Cao X, Harris KS, Lama J, Wimmer E. 1994. Studies with poliovirus polymerase 3Dpol. Stimulation of poly(U) synthesis in vitro by purified poliovirus protein 3AB. J. Biol. Chem. 269:29173&#x2013;29181</Citation><ArticleIdList><ArticleId IdType="pubmed">7961883</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotch SJ, Palant O. 1995. Poliovirus protein 3AB forms a complex with and stimulates the activity of the viral RNA polymerase, 3Dpol. J. Virol. 69:7169&#x2013;7179</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189638</ArticleId><ArticleId IdType="pubmed">7474138</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards OC, Ehrenfeld E. 1998. Effects of poliovirus 3AB protein on 3D polymerase-catalyzed reaction. J. Biol. Chem. 273:12832&#x2013;12840. 10.1074/jbc.273.21.12832</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.273.21.12832</ArticleId><ArticleId IdType="pubmed">9582311</ArticleId></ArticleIdList></Reference><Reference><Citation>Hope DA, Diamond SE, Kirkegaard K. 1997. Genetic dissection of interaction between poliovirus 3D polymerase and viral protein 3AB. J. Virol. 71:9490&#x2013;9498</Citation><ArticleIdList><ArticleId IdType="pmc">PMC230255</ArticleId><ArticleId IdType="pubmed">9371611</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons CP, Wolbers M, Nguyen MN, Whitehorn J, Shi PY, Young P, Petric R, Nguyen VV, Farrar J, Wills B. 2012. Therapeutics for dengue: recommendations for design and conduct of early-phase clinical trials. PLoS Negl. Trop. Dis. 6(9):e1752. 10.1371/journal.pntd.0001752</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0001752</ArticleId><ArticleId IdType="pmc">PMC3459884</ArticleId><ArticleId IdType="pubmed">23029567</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>